REVIEW

Appropriate antibiotic management of bacterial lower respiratory tract infections [version 1; peer review: 2 approved]

Charles Feldman ¹, Guy Richards²

¹Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg, 2193, South Africa

²Division of Critical Care, Charlotte Maxeke Johannesburg Academic Hospital, and Faculty of Health Sciences, University of Witwatersrand, 7 York Road, Parktown, Johannesburg, 2193, South Africa

V1 First published: 23 Jul 2018, 7(F1000 Faculty Rev):1121
<https://doi.org/10.12688/f1000research.14226.1>

Latest published: 23 Jul 2018, 7(F1000 Faculty Rev):1121
<https://doi.org/10.12688/f1000research.14226.1>

Abstract

Lower respiratory tract infections are the leading cause of infectious disease deaths worldwide and are the fifth leading cause of death overall. This is despite conditions such as pneumococcal infections and influenza being largely preventable with the use of appropriate vaccines. The mainstay of treatment for the most important bacterial lower respiratory tract infections, namely acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and community-acquired pneumonia (CAP), is the use of antibiotics. Yet despite a number of recent publications, including clinical studies as well as several systematic literature reviews and meta-analyses, there is considerable ongoing controversy as to what the most appropriate antibiotics are for the empiric therapy of CAP in the different settings (outpatient, inpatient, and intensive care unit). Furthermore, in the case of AECOPD, there is a need for consideration of which of these exacerbations actually need antibiotic treatment. This article describes these issues and makes suggestions for appropriately managing these conditions, in the setting of the need for antimicrobial stewardship initiatives designed to slow current emerging rates of antibiotic resistance, while improving patient outcomes.

Keywords

antibiotics, chronic obstructive pulmonary disease, community-acquired pneumonia, antimicrobial stewardship

Open Peer Review

Approval Status

	1	2
version 1		
23 Jul 2018		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Lars Bjerrum**, University of Copenhagen, Copenhagen, Denmark
Carles Llor, Primary Care Centre Via Roma, Barcelona, Spain
2. **David SC Hui**, The Chinese University of Hong Kong, Hong Kong, China

Any comments on the article can be found at the end of the article.

Corresponding author: Charles Feldman (feldmanc@medicine.wits.ac.za)

Author roles: **Feldman C:** Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing; **Richards G** : Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: CF has received honoraria for acting on the advisory board or speaker's bureau of pharmaceutical companies manufacturing or marketing macrolide antibiotics (Abbott, Aspen, Cipla, Pfizer, and Sandoz). GR has received honoraria for acting on the speaker's bureau of companies manufacturing or marketing antibiotics (Aspen and Bayer).

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Feldman C and Richards G. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Feldman C and Richards G. **Appropriate antibiotic management of bacterial lower respiratory tract infections [version 1; peer review: 2 approved]** F1000Research 2018, 7(F1000 Faculty Rev):1121 <https://doi.org/10.12688/f1000research.14226.1>

First published: 23 Jul 2018, 7(F1000 Faculty Rev):1121 <https://doi.org/10.12688/f1000research.14226.1>

Introduction

Lower respiratory tract infections (LRTIs), which generally are considered to include acute bronchitis, bronchiolitis, influenza, and pneumonia, are a significant cause of morbidity and mortality in patients worldwide^{1,2}. The Global Burden of Disease Study evaluated evidence for the global, regional, and national morbidity and mortality of LRTIs and indicated that, for 2015, LRTIs were the leading infectious disease cause of death and the fifth leading cause of death overall³. They estimated that LRTIs caused 2.74 million deaths and 103.0 million disability-adjusted life years (DALYs). While the burden had decreased in children younger than 5 years of age, it had increased in many regions for individuals older than 70 years. The study specifically investigated four etiologies—two bacterial and two viral—and noted that pneumococcal pneumonia was the most common etiology, which led to 1,517,388 deaths or 55.4% of LRTI deaths in all ages. Pneumococcal pneumonia was also a cause of a significant number of deaths in the elderly population worldwide (693,041 deaths in adults at least 70 years old). LRTIs are largely preventable causes of death, as vaccines are available against both influenza and pneumococcal pneumonia. Furthermore, while antiviral therapy is available for the treatment of influenza infections once they occur, the mainstay of treatment for community-acquired pneumonia (CAP) and acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD), which are the focus of this overview of the recent literature, is the use of antibiotics.

Overuse of antibiotics both in and out of hospital has resulted in an exponential increase in resistance globally. This has, and will, impact upon the ability to treat infections and be directly associated with increasing morbidity and mortality^{4,5}. This has resulted in numerous antimicrobial stewardship (AMS) programs—both in South Africa and internationally—designed to slow the rate at which organisms develop resistance and at the same time improve outcomes^{6,7}. AMS programs consist of two major pillars: first, infection prevention and control and then appropriate use of antibiotics, the latter of which will be the focus of this article. Appropriate use implies the correct indication, dose, duration, and administration method (that is, according to pharmacokinetic principles).

The actual antibiotic choice for bacterial LRTIs depends upon the likely organism; however, it is recognized that distinguishing viral from bacterial infections, both in CAP and in acute exacerbations of COPD, and recognizing non-infective COPD exacerbations are not always clear-cut processes. In fact, as many as 60% of COPD exacerbations may be due to viral infections, in particular rhinovirus, and in winter the influenza virus, and there is an increasing recognition of the important role for viruses in the etiology of CAP^{8,9}.

Although they are beyond the scope of this article, a brief review of biomarkers and the role they may play in the decision regarding the need for initiation, discontinuation, or duration of antibiotic treatment are of interest. Of the various biomarkers described, perhaps the most studied are C-reactive protein (CRP) and procalcitonin (PCT). One systematic review and meta-analysis evaluated the use of CRP to guide antibiotic

therapy in patients presenting to primary care with symptoms of acute respiratory infections and reported a significant reduction in antibiotic use with a slight increase in hospital admissions¹⁰. The European guideline on LRTIs indicates that out of the hospital setting, where chest radiographic confirmation of CAP is usually not available, a measurement of CRP in a patient suspected of having CAP can be performed (a point-of-care test is currently available)¹¹. They recommend that a level of less than 20 mg/L at presentation, in the presence of symptoms for at least 24 hours, makes pneumonia highly unlikely but that a level of more than 100 mg/L makes pneumonia likely.

With regard to PCT, there are some differences in the conclusions reached in the various studies. One systematic review and meta-analysis assessed the safety and efficacy of PCT for starting and stopping antibiotics in a range of patients with varying severity of acute respiratory tract infections in different clinical settings¹². The authors concluded that the use of PCT to guide initiation and duration of antibiotic treatment was associated with a lower risk of mortality, lower antibiotic consumption, and lower risk of antibiotic side effects. The authors, when using a patient-level meta-analysis, reached similar conclusions¹³. However, a recent study of PCT-guided use of antibiotics in the treatment of patients with suspected LRTIs did not result in less use of antibiotics than did usual care¹⁴. Furthermore, there is no point-of-care test available for the measurement of PCT, which is also costly.

Antibiotic treatment of community-acquired pneumonia

Antibiotics are the mainstay of therapy for CAP, and the initial antibiotic treatment needs to be empiric, as the causative organism or organisms are unknown at the time of presentation. However, there has been ongoing debate over a considerable period of time as to the most appropriate choice of initial empiric antibiotic treatment in the different settings: outpatient, inpatient, and intensive care unit (ICU). A number of national and international guidelines, which describe the appropriate management of CAP, have been developed; some of these have been updated recently or are in the process of being updated^{11,15,16}. It is clear when evaluating the guidelines that differences exist with regard to the various recommendations, including those for initial empiric antibiotic therapy^{11,15–17}.

For outpatient antibiotic therapy of CAP, the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guideline recommends a macrolide or tetracycline for previously healthy patients with no risk factors for drug-resistant *Streptococcus pneumoniae* (DRSP) infections. Furthermore, a respiratory fluoroquinolone or a beta-lactam plus a macrolide is recommended in the presence of certain comorbidities or risk factors for DRSP infections¹⁵. This is in contrast with the European guideline, which recommends amoxicillin or tetracycline for outpatient use with a macrolide or tetracycline being used only in the case of penicillin allergy, in settings with low levels of pneumococcal macrolide resistance¹¹. Similarly, the South African guideline recommends

amoxicillin as the treatment of choice, and a macrolide is to be used in the case of penicillin allergy in settings with low levels of pneumococcal macrolide resistance and other options are reserved for the elderly or for those with comorbidities or recent antibiotic use or both¹⁶. A recent literature review from Europe described the etiology and management of CAP in adults, which included both primary care and hospitalized cases¹⁸. The authors noted differences in antibiotic prescribing habits in the various regions of Europe. Beta-lactams were the most commonly prescribed class of antibiotics, and monotherapy was more common than combination therapy, but hospitalized patients more commonly received combination therapy than did outpatients. These differences in antibiotic recommendations could be ascribed to differences in the microbial etiology of CAP in the different regions, differences in the prevalence of antibiotic-resistant pathogens, differing patient populations, differences in national guideline recommendations, and other local factors, including regulatory requirements. A recent Cochrane review concluded that there was insufficient evidence from randomized controlled trials to make evidence-based recommendations regarding appropriate treatment in adult outpatients with CAP¹⁹. Owing to the low number of studies comparing the same antibiotic pairs, pooling of the data was also not possible; in general, the individual studies did not suggest any significant differences in the efficacy of the various antibiotics studied.

For inpatients with CAP, the IDSA/ATS guideline recommends the use of either a beta-lactam-macrolide combination or fluoroquinolone monotherapy for non-critically ill cases¹⁵; the European and South African guidelines have the addition of a macrolide to the beta-lactam as an option^{11,16}. Most of the guidelines recommend a combination therapy of a beta-lactam and macrolide or fluoroquinolone in those requiring ICU admission, and additional options are for possible pseudomonas infection^{11,15,16,20}. The most controversial area has been whether the use of a macrolide antibiotic should be an obligatory component of initial antibiotic treatment²¹. Earlier studies of hospitalized patients with moderately severe pneumonia suggested that beta-lactam monotherapy was not inferior to beta-lactam-macrolide combination therapy^{22,23}. However, as has been indicated by several investigators, those studies had certain limitations that make it difficult to accept their conclusions^{20,21}. A recent review highlighted all the studies documenting a benefit of combination therapy among inpatients; most of these studies were among CAP patients hospitalized in the ward and not the ICU¹⁷. Furthermore, Okumura *et al.* documented that in hospitalized CAP patients at low risk of drug-resistant pathogens, beta-lactam-macrolide combination treatment lowered 30-day mortality compared with beta-lactam therapy alone: adjusted odds ratio (OR) 0.28, 95% confidence interval (CI) 0.09–0.87²⁴.

There may still be some debate as to the need for adding a macrolide in less severely ill hospitalized cases. However, two matched case-control studies were published by the CAPUCI II Consortium on severe CAP patients admitted to the ICU^{25,26}. In the first, Gattarello *et al.* compared the outcome of two cohorts of critically ill patients with pneumococcal CAP from

different time periods (2001–2002 and 2008–2013)²⁵. The investigators noted that the mortality rate decreased by 18% from the earlier to the later cohort (together with other outcome benefits). This was determined on multivariate analysis to be associated with giving of the first dose of antibiotic within 3 hours (OR 0.36, 95% CI 0.15–0.87) and to the use of combination therapy (OR 0.19, 95% CI 0.07–0.51), which occurred more commonly in the second time period. The most frequently used antibiotic regimen was the combination of a cephalosporin with a macrolide, but other combinations included a cephalosporin and a fluoroquinolone. The second study was on patients with severe non-pneumococcal CAP, and the results were essentially similar²⁶. Once again, the most commonly used antibiotic regimen was a cephalosporin and a macrolide. Early antibiotic treatment (OR 0.07, 95% CI 0.02–0.22) and combined antibiotic therapy (OR 0.23, 95% CI 0.07–0.74), which occurred more commonly in the second time period, were independently associated with a lower ICU mortality.

Whereas a few studies have documented that combination therapy with a beta-lactam and a macrolide or fluoroquinolone has no additional benefit in critically ill patients with CAP^{27,28}, several recent studies have confirmed the benefit of combination therapy in this situation^{29–31}. For example, Pereira *et al.* documented that combination antibiotic therapy together with a macrolide was independently associated with a reduction in hospital stay (OR 0.17, 95% CI 0.06–0.51) and 6-month mortality (OR 0.21, 95% CI 0.07–0.57)³¹.

With regard to systematic reviews and meta-analyses of antibiotic therapy in critically ill patients with CAP, an early study concluded that there was a significant reduction in mortality when macrolides were used as part of treatment: 21% (836/4,036) versus 24% (1,369/5,814), risk ratio 0.82, 95% CI 0.70–0.97, $p = 0.02$ ³². When macrolide monotherapy was excluded, the mortality benefit of macrolides was still maintained. There was a trend towards better mortality with beta-lactam-macrolide therapy compared with beta-lactam-fluoroquinolone therapy: mortality with beta-lactam-macrolide therapy 20% (511/2,561 patients) versus 23% (386/1,680) with beta-lactam-fluoroquinolone therapy (risk ratio 0.83, 95% CI 0.67–1.03, $p = 0.09$)³². A number of more recent systematic reviews of antibiotic therapy in patients with CAP have been undertaken. Some that did not restrict the study to severely ill cases documented no benefit on 30-day mortality of beta-lactam-macrolide or beta-lactam-fluoroquinolone combination therapies over fluoroquinolone monotherapy^{33,34}. However, Horita *et al.* concluded that, compared with beta-lactam monotherapy, combination therapy with a beta-lactam plus macrolide may decrease all-cause mortality only in severe CAP³⁵. The authors did recommend caution in this interpretation, as the conclusion was based mainly on observational studies. Lastly, Lee *et al.*, in their systematic review and meta-analysis of patients with severe CAP, noted that the overall mortality of the beta-lactam-macrolide group was lower than that of the beta-lactam-fluoroquinolone group (19.4% versus 26.8%) (OR 0.68, 95% CI 0.49–0.94)³⁶. Furthermore, length of hospital stay was shorter in the former group compared with the latter group, although there was no difference in length of

ICU stay. However, despite these positive findings, the authors did indicate the need for caution with the conclusions because of the high risk of bias in the trials and methodological limitations.

The reason for the potential benefit of macrolide combination therapy in patients with CAP is unclear, but it is known that macrolide antibiotics have additional anti-inflammatory, immunomodulatory effects and do not directly lyse bacteria, which may play an important role. In the case of the pneumococcal infections, for example, lytic antibiotics increase the release of the pro-inflammatory toxin pneumolysin as well as cell-wall components, which may be associated with host tissue injury³⁷. For this reason, other investigators have studied the timing of combination antibiotic treatment^{38,39}. Such investigators have theorized that administering macrolides some time prior to the beta-lactam agent may improve patient outcomes because of the anti-inflammatory effects that attenuate the inflammatory response initiated by the beta-lactam-induced lysis of bacteria. Metersky *et al.* undertook a retrospective cohort study using electronic health records from a large database, comparing the outcome of CAP cases receiving a macrolide 1 hour before a cephalosporin compared with cases receiving a cephalosporin 1 hour before the macrolide³⁸. The adjusted mortality was about 30% lower in the former group compared with the latter group, although this did not reach statistical significance. There were also trends towards lower combined in-hospital mortality/hospice discharge and reduced length of stay. The authors concluded that it was worth pursuing this investigation with a larger cohort and perhaps in subsets of severe pneumonia cases. Furthermore, Peyrani *et al.* undertook a secondary analysis of data from the Community-Acquired Pneumonia Organisation (CAPO) database³⁹. They documented that, in CAP cases in whom a macrolide had been administered before the beta-lactam, compared with the reverse, the time to clinical stability (3 versus 4 days, $p = 0.011$), length of hospital stay (6 versus 7 days, $p = 0.002$) and mortality (3% versus 7.2%, $p = 0.228$) were lower.

Based on the findings of the majority of the studies, and in line with the recommendations of other investigators²¹, we would recommend that a combination of a beta-lactam and a macrolide be used in hospitalized and severely ill cases with CAP and that the macrolide be given prior to initiation of the beta-lactam. Furthermore, the antibiotics should be started as soon as possible after confirmation of the diagnosis of CAP. With regard to the fluoroquinolones, careful consideration needs to be given to their routine use for suspected CAP in areas in which tuberculosis (TB) is endemic because it is frequently difficult to clinically differentiate TB from CAP on initial presentation of patients⁴⁰. Therefore, there is concern that the use of fluoroquinolone in someone with TB but suspected of having CAP may lead to a delay in the diagnosis of TB and, moreover, be associated with the development of drug-resistant TB^{40,41}. Clearly, the above discussion has focused on empiric antibiotic therapy, and once the results of microbiological testing become available, antibiotic treatment should be tailored appropriately to the findings.

Two additional aspects of antibiotic therapy in patients with CAP need mention. The first is the importance of time to initiation/administration of antibiotics relative to the time of presentation with CAP. Although there has been the odd study suggesting that time to initiation of antibiotics has no impact on various patient outcomes⁴², this contention is not supported by the majority of additional studies^{25,26,43,44}. All of the studies from the CAPUCI II Consortium of critically ill patients with CAP indicated that early antibiotic administration (<3 hours) was independently associated with a lower ICU mortality^{25,26,43}. An additional study of hospitalized patients with CAP indicated that delay of the first dose of antibiotics beyond 4 hours was one of the independent predictors of mortality (adjusted OR 3.9)⁴⁴. Furthermore, the systematic review by Lee *et al.*³⁴, assessing three aspects of antibiotic therapy in hospitalized patients with CAP, noted that administration of antibiotics within 4 to 8 hours of hospital arrival was associated with a reduction in mortality, although the quality of evidence was assessed as being relatively poor. Thus, while it is clear that patients with severe CAP (especially those with septic shock) should receive antibiotics as soon as possible²⁰, the impact of time to antibiotic initiation on outcome in less severely ill cases is not clear²⁰. It seems prudent to initiate antibiotics as soon as possible in patients suspected of having CAP; however, it should not be at the expense of an adequate consideration of possible alternative diagnoses, including acute bronchitis, influenza, pulmonary embolism, and heart failure²⁰. In such patients, administration of an antibiotic would have no benefit, would be associated with potentially serious consequences, and would be contrary to AMS initiatives.

Lastly, some consideration should be given to the appropriate duration of antibiotic therapy for patients with CAP which has varied over time, even though earlier studies and even two meta-analyses indicated that shorter duration of therapy (for example, 7 days or less) could be safely and effectively used in patients with mild to moderately severe pneumonia⁴⁵. One recent multicenter non-inferiority randomized controlled trial of hospitalized patients with CAP randomly assigned patients at day 5 to an intervention or to a control group. The former were treated with antibiotics for a minimum of 5 days, and the antibiotic was stopped when the temperature had been 37.8°C or less for 48 hours and the patients had no more than one CAP-associated sign of clinical instability (this being in line with the recommendation of the IDSA/ATS guideline on CAP management)⁴⁶. The antibiotic treatment in the control group of patients was determined by the individual patient's physician. The results demonstrated non-inferiority of the shorter antibiotic course and supported the IDSA/ATS recommendations. In terms of potential limitations of the study, 60% of the patients were in low Pneumonia Severity Index (PSI) risk groups I–III and had a predicted mortality of less than 1%, and also there was a low rate of comorbid illnesses in the study population, which would limit generalizability to patients with significant comorbidity.

However, conversely, a more recent multicenter, non-inferiority, randomized controlled trial was undertaken in hospitalized

CAP patients who had reached clinical stability within 5 days of hospitalization, who were randomly assigned to a standard or individualized group⁴⁷. The latter had antibiotics discontinued 48 hours after reaching clinical stability, having had at least 5 days of antibiotics. The study was stopped early because of apparent inferiority of the individualized treatment over the standard treatment with regard to the primary outcome, which was early failure within 30 days. This difference (11.2% in the individualized group versus 7.4% in the standard group) was not statistically significant, but the safety committee interrupted the study because at the time this was the first study to evaluate clinical stability as a proxy to shorten antibiotic exposure in patients hospitalized with CAP and the 30-day mortality was higher in the individualized versus the standard group.

However, other studies and reviews have supported shorter duration of antibiotic therapy in patients with CAP and suggested that the use of biomarkers, such as PCT, may be useful in guiding both the initiation and the duration of antibiotic treatment^{48,49}. One group of investigators documented that an implementation strategy, tailored to identify previous barriers to early switch, was associated with a reduced duration of intravenous therapy⁵⁰. Another implemented a dedicated CAP team to manage low-risk, hospitalized CAP patients, which resulted in a reduced hospital length of stay, time to switch from intravenous antibiotics, and antibiotic duration without any adverse events⁵¹.

It is interesting to briefly mention non-antibiotic adjunctive therapies, which—though clearly beyond the scope of this review—continue to be evaluated in critically ill patients with CAP, in whom the mortality remains high despite apparently appropriate antibiotic treatment. A number of such therapies have been studied, of which the use of corticosteroids (CSs) appears to be most promising, and a number of positive randomized controlled trials and systematic literature reviews have been published in recent years^{52,53}. Most recently, the Cochrane database of systematic reviews updated its 2011 review of randomized controlled trials of systemic CS therapy, as adjunct to antibiotic therapy versus placebo or no CS, and concluded that CS therapy significantly reduces morbidity (various end-points) and mortality (relative risk 0.58, 95% CI 0.40–0.84) in adults with severe CAP; the number needed to treat for additional beneficial outcome was 18 patients (95% CI 12–49) to prevent one death⁵⁴. CSs also significantly reduced morbidity, but not mortality, for non-severe CAP in adults, and although there were more adverse events in the CS group (especially hyperglycemia), the harms did not outweigh the benefits. The South African CAP guideline makes some specific recommendations for the use of CSs in patients with severe CAP¹⁶, and it would seem likely that as the older CAP guidelines are updated, more specific recommendations regarding adjunctive therapy for CAP will be included.

Antibiotics for acute exacerbations of chronic obstructive pulmonary disease

Antibiotics are used in two instances in COPD: in order to treat an infection associated with an acute exacerbation (acute

exacerbations of COPD [AECOPD]) and for prophylaxis. We have previously described a treatment algorithm designed to limit antibiotic use and assist clinicians in the outpatient setting. This algorithm was based upon severity of symptoms according to the Anthonisen criteria and point-of-care testing using the CRP where the clinical criteria are equivocal regarding severity^{55,56}. Although the study by Anthonisen *et al.*⁵⁶ is old, various other studies have confirmed the value of antibiotics, particularly in the severe exacerbation; however, perhaps the most important of these criteria is sputum purulence and, as mentioned above, the presence of an elevated CRP^{55,57–60} (Figure 1). In addition, more recently, a meta-analysis that included four trials and 679 patients found that the use of PCT significantly reduced antibiotic use with an OR of 0.26 (95% CI 0.14–0.50, $p < 0.0001$) without increasing clinical failure and mortality⁶¹. Readmission rates and subsequent exacerbations were similar in the two groups. As discussed previously, a reduction of antibiotic use is a critical component of AMS.

The most common bacterial organisms isolated in AECOPD remain *Haemophilus influenzae* and *S. pneumoniae*; however, *Moraxella catarrhalis* and the atypical organisms may also be seen⁶². Viral infections may predispose patients to bacterial infections, and the specific bacteria isolated depend on factors such as age of more than 65 years, steroid use, comorbid illness such as cardiac disease, structural lung disease, or more severe COPD—Global Initiative for Chronic Obstructive Lung Disease (GOLD) 3–4 lung functions—and previous antibiotic use in the past 3 months (as would be the case in frequent exacerbators)^{63–65}. In fact, some studies indicate that more resistant organisms such as *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Acinetobacter* and *Enterobacter* species are increasingly being seen, particularly in developing countries, even without these risk factors^{66–69}. This implies that the choice of agent depends on both risk factors and local epidemiology. However, we would recommend that therapy be initiated with *H. influenzae* and *S. pneumoniae* in mind⁷⁰.

As such, the initial antibiotic choice would be amoxicillin (or amoxicillin–clavulanate where beta-lactamase production by *H. influenzae* is prevalent) or a fluoroquinolone. However, the US Food and Drug Administration has recommended that the latter be used only as a last resort agent and be reserved for use in patients who have no other treatment options because of both side effects and potential collateral damage⁷¹.

Other agents, such as the cephalosporins cefuroxime or cefpodoxime, may be appropriate as they are active against *H. influenzae* and higher doses would also be effective against the pneumococcus. The extended-spectrum macrolides may be effective against the former but increasing resistance of the pneumococcus has limited their utility. For hospitalized patients with risks for pseudomonas or other more-resistant organisms, anti-pseudomonal agents such as piperacillin–tazobactam, cefepime, or ciprofloxacin may be considered. It is recommended that these patients have a sputum culture performed on admission⁷².

COPD: Chronic obstructive pulmonary disease

CRP: C-reactive protein

POCT: Point of Care Testing

Reproduced with permission from the South African Medical Journal, reference 41.

Figure 1. Recommendations for antibiotic use in non-hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease. COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; POCT, point-of-care testing. Reproduced with permission from the *South African Medical Journal*⁴¹.

The duration of the antibiotic “course” has been somewhat controversial in that, for a long time, there has been a mistaken belief that longer courses decrease resistance and improve outcome. This is patently untrue, and in many diseases (including COPD) shorter courses have had equivalent outcomes with fewer adverse events⁷³. As such, we would recommend 5 days as being the optimal duration for most AECOPD^{74–76}.

The dosing of each antibiotic should be according to pharmacokinetic principles. The beta-lactams are time-dependent agents; as such, the target should be to exceed the minimum inhibitory concentration by as much time as possible, both to limit resistance and to improve outcome. The fluoroquinolones, as concentration-dependent agents, should preferably be administered once daily to achieve a maximal area under

the inhibitory curve (AUC) or an area under the curve-to-MIC ratio (AUC/MIC). Unfortunately, owing to toxicity issues, this is not possible with all agents in practice. For example, if an agent such as ciprofloxacin is going to be used, it must be administered twice daily because of suspected or documented infection with some of the Gram-negative pathogens described above^{77,78}. The concept of “short-course high-dose antibiotic therapy” embodies these principles and should be employed wherever possible.

Of interest, established guidelines for the management of COPD exacerbations such as those of the GOLD initiative are generally not well adhered to and this includes antibiotic strategies. In a recent study evaluating compliance, 64 (68.1%) of the 94 patients received antibiotics, of which only 71.9% were appropriate⁷⁹.

Inhaled antibiotics have not been well evaluated; however, one study that used nebulized tobramycin twice daily for 14 days in patients with severe COPD colonized with multidrug-resistant *P. aeruginosa* demonstrated a 42% decrease in AECOPD compared with the previous 6 months and also a marked reduction in markers of inflammation, indicating a potential role for this modality of therapy⁸⁰.

An alternative use for antibiotics in patients with COPD has been prophylaxis for exacerbations, which are predictive of a worse outcome in COPD, and any means that might reduce them may potentially also improve long-term survival and quality of life⁸¹. Numerous agents used for COPD have been shown to reduce exacerbations, and these include the long-acting antimuscarinic agents, inhaled CSs, and the phosphodiesterase 4 inhibitors. Antibiotics, specifically the macrolides, have also been shown to provide benefit; however, the exact mechanism has not been fully elucidated^{82–84}. Different anti-inflammatory effects have been investigated *in vitro* but not proven *in vivo*^{85,86}.

Doses vary, but the most frequent doses of azithromycin administered have been 250 or 500 mg three times a week. There are possible side effects from the use of these agents for this purpose, and these include resistance of bacteria and non-tuberculous mycobacteria, drug–drug interactions, QT prolongation, reversible deafness, and gastrointestinal upset⁸⁵. However, when used in selected patients, the macrolides are safe and cost effective^{86,87}.

In line with stewardship principles, vaccination strategies, if effective, would be valuable in reducing antibiotic use. Whereas vaccination with the pneumococcal polysaccharide vaccine has provided inconsistent benefit in COPD, influenza vaccine—in particular, when combined with the pneumococcal polysaccharide vaccine (studies using the conjugate vaccine are not available but it would be expected to be better)—reduces hospitalization for pneumonia, death, death from influenza, and death from pneumonia⁸⁸. In addition, a meta-analysis of the use of an oral, whole-cell, non-typeable *H. influenzae* (NTHi) vaccine versus placebo in patients with AECOPD found a statistically significant 80% increase in antibiotic courses per person in the placebo group (risk ratio 1.81, 95% CI 1.35–2.44, $p < 0.0001$) was noted⁸⁹.

Conclusions

CAP and bacterial AECOPD are significant LRTIs associated with considerable morbidity and mortality. Despite numerous clinical studies as well as systematic reviews and meta-analyses, there is still ongoing debate as to the appropriate treatment of CAP, particularly in severely ill cases, and additionally which AECOPD actually need antibiotics. These issues are discussed in detail in the article, and recommendations are given on the basis of the authors’ collective experience. Furthermore, it is important to remember that, with regard to antibiotic use, these agents are a potentially life-saving resource that must be used wisely both in terms of the specific agent, duration, and dose and in the correct circumstances.

Competing interests

CF has received honoraria for acting on the advisory board or speaker’s bureau of pharmaceutical companies manufacturing or marketing macrolide antibiotics (Abbott, Aspen, Cipla, Pfizer, and Sandoz). GR has received honoraria for acting on the speaker’s bureau of companies manufacturing or marketing antibiotics (Aspen and Bayer).

Grant information

The author(s) declared that no grants were involved in supporting this work.

Acknowledgements

CF is supported by the National Research Foundation of South Africa.

References

1. **Chapter 18. Acute lower respiratory infections.** ERS White Book. (last accessed 20 February, 2018); 210–223.
[Reference Source](#)
2. Greene G, Hood K, Little P, *et al.*: **Towards clinical definitions of lower respiratory tract infection (LRTI) for research and primary care practice in Europe: an international consensus study.** *Prim Care Respir J.* 2011; 20(3): 299–306, 6 p following 306.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. GBD 2015 LRI Collaborators: **Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015.** *Lancet Infect Dis.* 2017; 17(11): 1133–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
4. Review on antimicrobial resistance: **Tackling a global health crisis: Initial steps.** 2015. (last accessed 27 February, 2018).
[Reference Source](#)

5. Brink A, Feldman C, Richards G, *et al.*: **Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer.** *S Afr Med J.* 2008; **98**(8): 586, 588, 590 passim.
[PubMed Abstract](#)
6. **Mission Statement of the South African Antibiotic Stewardship Programme.** (last accessed 27 February, 2018).
[Reference Source](#)
7. **UK recommendations for combating antimicrobial resistance: a review of 'antimicrobial stewardship: systems and processes for effective antimicrobial medicine use'.** (last accessed 28 February, 2018).
[Reference Source](#)
8. Seemungal T, Harper-Owen R, Bhowmik A, *et al.*: **Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.** *Am J Respir Crit Care Med.* 2001; **164**(9): 1618–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. **F** Jain S, Self WH, Wunderink RG, *et al.*: **Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.** *N Engl J Med.* 2015; **373**(5): 415–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
10. Aabenhus R, Jensen JU, Jørgensen KJ, *et al.*: **Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care.** *Cochrane Database Syst Rev.* 2014; (11): CD010130.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Woodhead M, Blasi F, Ewig S, *et al.*: **Guidelines for the management of adult lower respiratory tract infections—summary.** *Clin Microbiol Infect.* 2011; **17** Suppl 6: 1–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. **F** Schuetz P, Wirz Y, Sager R, *et al.*: **Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.** *Cochrane Database Syst Rev.* 2017; **10**: CD007498.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
13. **F** Schuetz P, Wirz Y, Sager R, *et al.*: **Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis.** *Lancet Infect Dis.* 2018; **18**(1): 95–107.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
14. **F** Huang DT, Yealy DM, Filbin MR, *et al.*: **Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection.** *N Engl J Med.* 2018.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
15. Mandell LA, Wunderink RG, Anzueto A, *et al.*: **Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.** *Clin Infect Dis.* 2007; **44** Suppl 2: S27–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Boyles TH, Brink A, Calligaro GL, *et al.*: **South African guideline for the management of community-acquired pneumonia in adults.** *J Thorac Dis.* 2017; **9**(6): 1469–502.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Woodhead M, Noor M: **Empirical antibiotic management of adult CAP.** In: Chalmers JD, Pletz MW, Aliberti S, editors. *Community-Acquired Pneumonia.* European Respiratory Society; 2014: 140–154.
[Publisher Full Text](#)
18. Torres A, Blasi F, Peetermans WE, *et al.*: **The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review.** *Eur J Clin Microbiol Infect Dis.* 2014; **33**(7): 1065–79.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Pakhale S, Mulpuru S, Verheij TJ, *et al.*: **Antibiotics for community-acquired pneumonia in adult outpatients.** *Cochrane Database Syst Rev.* 2014; (10): CD002109.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Bender MT, Niederman MS: **Principles of Antibiotic Management of Community-Acquired Pneumonia.** *Semin Respir Crit Care Med.* 2016; **37**(6): 905–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Waterer G: **Empiric antibiotics for community-acquired pneumonia: A macrolide and a beta-lactam please!** *Respirology.* 2018; **23**(5): 450–1.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. **F** Garin N, Genné D, Carballo S, *et al.*: **β -Lactam monotherapy vs β -lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.** *JAMA Intern Med.* 2014; **174**(12): 1894–901.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
23. **F** Postma DF, van Werkhoven CH, van Elden LJ, *et al.*: **Antibiotic treatment strategies for community-acquired pneumonia in adults.** *N Engl J Med.* 2015; **372**(14): 1312–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
24. **F** Okumura J, Shindo Y, Takahashi K, *et al.*: **Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β -lactam plus macrolide combination therapy.** *Respirology.* 2018; **23**(5): 526–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
25. **F** Gattarello S, Borgatta B, Solé-Violán J, *et al.*: **Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013).** *Chest.* 2014; **146**(1): 22–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
26. **F** Gattarello S, Lagunes L, Vidaur L, *et al.*: **Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study.** *Crit Care.* 2015; **19**: 335.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
27. **F** Rahmel T, Asmussen S, Karlik J, *et al.*: **Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.** *BMC Anesthesiol.* 2017; **17**(1): 78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
28. Adrie C, Schwebel C, Garrouste-Georges M, *et al.*: **Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.** *Crit Care.* 2013; **17**(6): R265.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. **F** Sakamoto Y, Yamauchi Y, Yasunaga H, *et al.*: **Guidelines-concordant empiric antimicrobial therapy and mortality in patients with severe community-acquired pneumonia requiring mechanical ventilation.** *Respir Investig.* 2017; **55**(1): 39–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
30. **F** De la Calle C, Ternavasio-de la Vega HG, Morata L, *et al.*: **Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis.** *J Infect.* 2018; **76**(4): 342–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
31. **F** Pereira JM, Gonçalves-Pereira J, Ribeiro O, *et al.*: **Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.** *J Crit Care.* 2018; **43**: 183–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
32. **F** Sligl WI, Asadi L, Eurich DT, *et al.*: **Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis.** *Crit Care Med.* 2014; **42**(2): 420–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
33. Raz-Pasteur A, Shasha D, Paul M: **Fluoroquinolones or macrolides alone versus combined with β -lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.** *Int J Antimicrob Agents.* 2015; **46**(3): 242–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. **F** Lee JS, Giesler DL, Gellad WF, *et al.*: **Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.** *JAMA.* 2016; **315**(6): 593–602.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
35. **F** Horita N, Otsuka T, Haranaga S, *et al.*: **Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis.** *Respirology.* 2016; **21**(7): 1193–200.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. **F** Lee JH, Kim HJ, Kim YH: **Is β -Lactam Plus Macrolide More Effective than β -Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.** *J Korean Med Sci.* 2017; **32**(1): 77–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
37. Brown LA, Mitchell AM, Mitchell TJ: ***Streptococcus pneumoniae* and lytic antibiotic therapy: are we adding insult to injury during invasive pneumococcal disease and sepsis?** *J Med Microbiol.* 2017; **66**: 1253–1256.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. **F** Metersky ML, Priya A, Mortensen EM, *et al.*: **Association Between the Order of Macrolide and Cephalosporin Treatment and Outcomes of Pneumonia.** *Open Forum Infect Dis.* 2017; **4**(3): ofx141.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
39. Peyrani P, Wiemken TL, Metersky ML, *et al.*: **The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.** *Infect Dis (Lond).* 2018; **50**(1): 13–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Grossman RF, Hsueh PR, Gillespie SH, *et al.*: **Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.** *Int J Infect Dis.* 2014; **18**: 14–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Low DE: **Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective.** *Clin Infect Dis.* 2009; **48**(10): 1361–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Marti C, John G, Genné D, *et al.*: **Time to antibiotics administration and outcome in community-acquired pneumonia: Secondary analysis of a randomized controlled trial.** *Eur J Intern Med.* 2017; **43**: 58–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. **F** Rello J, Diaz E, Mañez R, *et al.*: **Improved survival among ICU-hospitalized patients with community-acquired pneumonia by unidentified organisms: a multicenter case-control study.** *Eur J Clin Microbiol Infect Dis.* 2017; **36**(1): 123–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
44. **F** Iroezindu MO, Isiguzo GC, Chima EI, *et al.*: **Predictors of in-hospital**

- mortality and length of stay in community-acquired pneumonia: a 5-year multi-centre case control study of adults in a developing country. *Trans R Soc Trop Med Hyg.* 2016; **110**(8): 445–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
45. Shaddock EJ, Feldman C: Shorter antibiotic courses in community-acquired pneumonia-ready for prime time. *J Thorac Dis.* 2016; **8**(12): E1628–E1631.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. **F** Uranga A, España PP, Bilbao A, *et al.*: Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. *JAMA Intern Med.* 2016; **176**(9): 1257–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 47. **F** Aliberti S, Ramirez J, Giuliani F, *et al.*: Individualizing duration of antibiotic therapy in community-acquired pneumonia. *Pulm Pharmacol Ther.* 2017; **45**: 191–201.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 48. Pinzone MR, Cacopardo B, Abbo L, *et al.*: Duration of antimicrobial therapy in community acquired pneumonia: less is more. *ScientificWorldJournal.* 2014; **2014**: 759138.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 49. **F** Kaziani K, Sotiriou A, Dimopoulos G: Duration of pneumonia therapy and the role of biomarkers. *Curr Opin Infect Dis.* 2017; **30**(2): 221–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 50. Engel MF, Bruns AH, Hulscher ME, *et al.*: A tailored implementation strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after study. *Eur J Clin Microbiol Infect Dis.* 2014; **33**(11): 1897–908.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Marcos PJ, Restrepo MI, Sanjuán P, *et al.*: Community-acquired pneumonia team decreases length of stay in hospitalized, low-risk patients with pneumonia. *Hosp Pract (1995).* 2013; **41**(3): 7–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. **F** Sibila O, Rodrigo-Troyano A, Torres A: Nonantibiotic Adjunctive Therapies for Community-Acquired Pneumonia (Corticosteroids and Beyond): Where Are We with Them? *Semin Respir Crit Care Med.* 2016; **37**(6): 913–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 53. Feldman C, Anderson R: Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. *J Thorac Dis.* 2016; **8**(3): E162–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. **F** Stern A, Skalsky K, Avni T, *et al.*: Corticosteroids for pneumonia. *Cochrane Database Syst Rev.* 2017; **12**: CD007720.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 55. Brink AJ, van Wyk J, Moodley VM, *et al.*: The role of appropriate diagnostic testing in acute respiratory tract infections: An antibiotic stewardship strategy to minimise diagnostic uncertainty in primary care. *S Afr Med J.* 2016; **106**(6): 30–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Anthonisen NR, Manfreda J, Warren CP, *et al.*: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med.* 1987; **106**(2): 196–204.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Allegra L, Blasi F, de Bernardi B, *et al.*: Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. *Pulm Pharmacol Ther.* 2001; **14**(2): 149–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. **F** Daniels JM, Snijders D, de Graaff CS, *et al.*: Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2010; **181**(2): 150–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 59. **F** Llor C, Moragas A, Hernández S, *et al.*: Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2012; **186**(8): 716–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 60. Miravittles M, Moragas A, Hernández S, *et al.*: Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? *Chest.* 2013; **144**(5): 1571–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. **F** Lin C, Pang Q: Meta-analysis and systematic review of procalcitonin-guided treatment in acute exacerbation of chronic obstructive pulmonary disease. *Clin Respir J.* 2018; **12**(1): 10–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 62. **F** Ra SW, Kwon YS, Yoon SH, *et al.*: Sputum bacteriology and clinical response to antibiotics in moderate exacerbation of chronic obstructive pulmonary disease. *Clin Respir J.* 2018; **12**(4): 1424–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 63. Miravittles M, Murio C, Guerrero T: Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. *Eur Respir J.* 2001; **17**(5): 928–33.
[PubMed Abstract](#)
 64. Wilson R, Jones P, Schaberg T, *et al.*: Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. *Thorax.* 2006; **61**(4): 337–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. *N Engl J Med.* 2008; **359**(22): 2355–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Sharan H: Aerobic Bacteriological Study of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. *J Clin Diagn Res.* 2015; **9**(8): DC10–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Narayanagowda D, Golia S, Jaiswal J, *et al.*: A bacteriological study of acute exacerbation of chronic obstructive pulmonary disease over a period of one year. *Int J Res Med Sci.* 2015; **3**(11): 3141–6.
[Publisher Full Text](#)
 68. **F** Kuwal A, Joshi V, Dutt N, *et al.*: A Prospective Study of Bacteriological Etiology in Hospitalized Acute Exacerbation of COPD Patients: Relationship with Lung Function and Respiratory Failure. *Turk Thorac J.* 2018; **19**(1): 19–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 69. **F** Rodrigo-Troyano A, Suarez-Cuartin G, Peiró M, *et al.*: *Pseudomonas aeruginosa* resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. *Respirology.* 2016; **21**(7): 1235–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 70. Nakou A, Papaparaskevas J, Diamantea F, *et al.*: A prospective study on bacterial and atypical etiology of acute exacerbation in chronic obstructive pulmonary disease. *Future Microbiol.* 2014; **9**(11): 1251–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. (last accessed 27 February 2018).
[Reference Source](#)
 72. Miravittles M, Soler-Cataluña JJ, Calle M, *et al.*: Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. *Arch Bronconeumol.* 2017; **53**(6): 324–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. **F** Stolbrink M, Amiry J, Blakey JD: Does antibiotic treatment duration affect the outcomes of exacerbations of asthma and COPD? A systematic review. *Chron Respir Dis.* 2017; **14**: 1479972317745734.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 74. **F** Llewellyn MJ, Fitzpatrick JM, Darwin E, *et al.*: The antibiotic course has had its day. *BMJ.* 2017; **358**: j3418.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 75. Falagas ME, Avgeri SG, Matthaïou DK, *et al.*: Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. *J Antimicrob Chemother.* 2008; **62**(3): 442–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. El Moussaoui R, Roede BM, Speelman P, *et al.*: Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. *Thorax.* 2008; **63**(5): 415–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Drusano GL: From lead optimization to NDA approval for a new antimicrobial: Use of pre-clinical effect models and pharmacokinetic/pharmacodynamic mathematical modeling. *Bioorg Med Chem.* 2016; **24**(24): 6401–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Drusano GL, Louie A, MacGowan A, *et al.*: Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. *Antimicrob Agents Chemother.* 2015; **60**(3): 1183–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. **F** Lipari M, Smith AL, Kale-Pradhan PB, *et al.*: Adherence to GOLD Guidelines in the Inpatient COPD Population. *J Pharm Pract.* 2018; **31**(1): 29–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 80. Dal Negro R, Micheletto C, Tognella S, *et al.*: Tobramycin Nebulizer Solution in severe COPD patients colonized with *Pseudomonas aeruginosa*: effects on bronchial inflammation. *Adv Ther.* 2008; **25**(10): 1019–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Wedzicha JA, Singh R, Mackay AJ: Acute COPD exacerbations. *Clin Chest Med.* 2014; **35**(1): 157–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. Yamaya M, Azuma A, Takizawa H, *et al.*: Macrolide effects on the prevention of COPD exacerbations. *Eur Respir J.* 2012; **40**(2): 485–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Donath E, Chaudhry A, Hernandez-Aya LF, *et al.*: A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease. *Respir Med.* 2013; **107**(9): 1385–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 84. **F** Uzun S, Djamin RS, Kluytmans JA, *et al.*: Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. *Lancet Respir Med.* 2014; **2**(5): 361–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 85. Parameswaran GI, Sethi S: Long-term macrolide therapy in chronic obstructive pulmonary disease. *CMAJ.* 2014; **186**(15): 1148–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

86. Spagnolo P, Fabbri LM, Bush A: **Long-term macrolide treatment for chronic respiratory disease.** *Eur Respir J.* 2013; **42**(1): 239–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Simoons S, Laekeman G, Decramer M: **Preventing COPD exacerbations with macrolides: a review and budget impact analysis.** *Respir Med.* 2013; **107**(5): 637–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Gilchrist SA, Nanni A, Levine O: **Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers.** *Am J Public Health.* 2012; **102**(4): 596–605.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Teo E, Lockhart K, Purchuri SN, *et al.*: ***Haemophilus influenzae* oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.** *Cochrane Database Syst Rev.* 2017; **6**: CD010010.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. David SC Hui

Department of Medicine and Therapeutics, Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China

Competing Interests: No competing interests were disclosed.

2. Lars Bjerrum

Section of General Practice and Research Unit for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

Carles Llor

Primary Care Centre Via Roma, Barcelona, Spain

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research